Blocking Oxidized Lipoproteins
Inflammation is the body’s way of protecting itself against infection and injury. When activated appropriately by the immune system, acute inflammation can be life-saving response; when activated chronically, it can become very harmful, causing many serious diseases, including cardiovascular disease, cancer, rheumatological diseases, and metabolic disease. Available drugs and biologics, called immunomodulators, can reduce inflammation by modulating various immune system pathways, however, these treatments can interfere with normal immune system function. This leaves patients susceptible to serious side effects, such as fatal infections and cancers.
Abcentra has invented a way to target inflammatory responses specifically from oxidized lipoproteins. Targeting inflammation in this highly selective manner creates the possibility of reducing chronic inflammation without interfering with normal immune system functions, like fighting infection and cancer. By intervening at the intersection of accumulated damage from oxidative stress to lipoproteins and immune system activation, Abcentra aims to offer new and compelling treatments for a variety of inflammatory diseases.
Orticumab is a fully-human antibody against oxidized low-density lipoprotein (oxLDL). It is highly selective for a specific epitope on oxidized apoB-100, the protein component of oxLDL.
Orticumab has demonstrated the potential to reduce atherosclerosis and change plaque phenotype in rodent models. Additionally, orticumab has been shown to favorably modulate biomarkers of inflammation and insulin resistance in obese non-human primates. These cardio-metabolic effects are hypothesized to be mediated by targeted inhibition of inflammatory responses to oxLDL.
Mechanism of Action
Orticumab blocks inflammatory responses to oxLDL